BioCentury
ARTICLE | Top Story

Boehringer returns olmutinib rights to Hanmi

September 30, 2016 7:00 AM UTC

Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) fell W112,000 (18%) to W508,000 after Boehringer Ingelheim GmbH (Ingelheim, Germany) said it returned rights for olmutinib ( HM61713; BI 1482694) to the Korean company. According to Boehringer, the Korean Ministry of Food and Drug Safety reported three serious skin reactions, including one fatal case, in a drug safety letter for the candidate.

Boehringer told BioCentury the ministry's letter described two cases of toxic epidermal necrolysis and one non-fatal case of Stevens-Johnson syndrome. The company said the toxic epidermal necrolysis was reported in the Phase I/II HM-EMSI-101 study and the Phase II HM-ESMI-102 trial. Both studies are evaluating olmutinib to treat non-small cell lung cancer (NSCLC). ...